Renal Cell Carcinoma

This article will review the recent advances that form the current framework of therapy for RCC, as well as summarize key areas of progress and innovation in the evolving treatment paradigms for this disease.
• Renal Cancer Therapeutics: Now What?
• Metastatic RCC: Moving Towards a Chronic Disease

Second Opinion series: The patient is a 43-year-old man who was initially evaluated at an outside institution for unexplained anemia and who was found to have a large right kidney mass.
• Malignant Angiomyolipoma: a Rare Entity With Unusual Biology
• An Approach to the Management of Rare Tumors

This article reviews the existing data to formulate an overall management strategy of metastatic RCC patients and discusses ongoing investigative efforts including sequencing, combination therapy and novel agents.
• Renal Cell Carcinoma: The Fastest Evolving Tumor
• A Fourth Generation of Therapies for Metastatic Kidney Cancer?

The patient is a 39-year-old Caucasian male who presented with a right renal mass and painless gross hematuria. He underwent a right laparoscopic radical nephrectomy and the final pathology revealed a carcinoid tumor.

A 3-year-old child was brought to the physician’s office after the mother felt a mass in the abdominal area. Imaging revealed the presence of a mass that appeared to be in the right kidney. Surgical resection of the tumor was performed.

A 28-year-old, slightly obese Caucasian woman presented with a long-standing history of intermittently painful “bumps” on both shoulders and her upper back. Review of systems disclosed regular but very heavy menstrual periods, often lasting for 7 to 9 days, and chronic constipation.

A 60-year-old woman developed metastatic renal cell carcinoma and was given oral sorafenib. Three weeks after commencing treatment, the patient became febrile without signs of localized infection and rapidly developed a nonpruritic, slightly tender cutaneous eruption.

A 56-year-old man with renal cell carcinoma developed widely metastatic disease post nephrectomy, for which he was receiving cyclic sunitinib therapy (50 mg daily for 4 weeks, followed by a 2-week rest period). Toward the end of his second cycle of therapy, he developed minimally pruritic, bright red erythema and fine scale involving both sides of the scrotum.